Portal de Periódicos da CAPES

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

2023; Adis, Springer Healthcare; Volume: 13; Issue: 3 Linguagem: Inglês

10.1007/s13555-023-00893-4

2193-8210

Jan Hugo, Martina Kojanová, Barbora Turková, Spyridon Gkalpakiotis, Zdenek Antal, Petr Arenberger, Jirina Bartonová, Linda Blahova, Petra Brodská, P. Boháč, Hana Bučková, Martin Cetkovsky, Petra Cetkovská, Jana Cadova, Dominika Diamantova, Magdalena Dobiasova, Hana Duchkova, Jorga Fialová, Olga Filipovska, Jana Földesová, Petra Gkalpakioti, Martina Grycova, Jiří Horažďovský, Eva Horka, Katerina Hrazdirova, Eduard Hrncir, Jana Chlebková, Jaromira Janku, Lucie Růžičková Jarešová, Renáta Kopová, Dora Kovandova, Silvie Krchova, Lenka Kulmanova, Natalie Kunesova, Iva Lomicová, Romana Machackova, Alena Machovcová, Hana Malíková, Martina Matzenauer, Miroslav Nečas, Helena Němcová, Radka Neumannova, Michaela Nováková, Jitka Osmerova, Veronika Pallova, Lucie Petru, Blanka Pinková, Zuzana Plzáková, Marie Policarová, Tomáš Pospíšil, Filip Rob, M Salavec, Marie Selerová, Veronika Slonková, Jiri Strok, Ivana Strouhalova, David Stuchlik, Alena Stumpfova, Jaroslav Ševčík, Jan Šternberský, Kateřina Švarcová, Katerina Tepla, M Tichý, H Tomková, Yvetta Vantuchová, Ivana Vejrova, Iva Zampachova,

Pharmaceutical studies and practices

Real-world data on the long-term use of guselkumab for treatment of psoriasis are still limited. We aimed to evaluate long-term efficacy, safety, and drug survival of guselkumab in a real-world setting. This is a retrospective study analyzing Czech Republic registry (BIOREP) data of patients treated with guselkumab. In total, 333 patients were included. Improvement in Psoriasis Area and Severity Index (PASI) score was significant. Mean PASI score decreased from 16 at baseline to 0.7, 0.9, and 0.8 after 12, 24, and 36 months, respectively. Absolute PASI scores of ≤ 3 and ≤ 1 were achieved in 93.9% and 77.9%, 94.2% and 71.0%, and 94.8% and 70.7% of patients after 12, 24, and 36 months, respectively. Response PASI 90 and PASI 100 were attained in 81.8% and 57.1%, 75.4% and 50.7%, and 75.9% and 55.2% of patients after 12, 24, and 36 months, respectively. The percentage of patients achieving PASI 90 and PASI 100 responses was higher throughout the study in bio-naive and in normal-weight patients, while presence of psoriatic arthritis had no influence. Improvement in Dermatology Life Quality Index (DLQI) score was also significant; mean DLQI score decreased from 14.2 at baseline to 0.9, 1.0, and 0.7 after 12, 24, and 36 months, respectively. Patients with PASI 100 had lower mean DLQI throughout the study compared with patients with PASI 90. Major reason for discontinuation was loss of effectiveness in 7.1% of patients, while only 0.6% were due to adverse events. Overall cumulative drug survival was high, with only a minimal decline over time, reaching 91.6%, 87.0%, and 85.5% after 12, 24, and 36 months, respectively. Drug survival was not affected by previous biological treatment, patient weight, or presence of psoriatic arthritis. This real-world study demonstrated the long-term effectiveness, good safety profile, and high drug survival of guselkumab treatment over a period of 36 months.